This information is for healthcare professionals only.
This non-promotional video is organised and funded by Bristol Myers Squibb.
Disclaimer: The information in this presentation has been prepared for medical and scientific purposes. This information should not be construed as an inducement to use CAR-T cell product for unapproved indications. Bristol Myers Squibb does not recommend the use of its approved products in any manner inconsistent with that described in the full Prescribing Information.
There is information included that pertains to investigational therapy(ies) that have not been approved for use in your country. There is no guarantee that the agent(s) will receive health authority approval or become commercially available in any country for the uses being investigated.
Disclosure: Campbell has nothing to disclose. Riley has received consulting or advisory board fees from Cabaletta Bio, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Horizon/Amgen, Immunic AG, NovartisTG Therapeutics, and Viracta. Patel has received consulting fees from Abbvie, Adaptive, ADC, AstraZeneca, Beigene, Bristol Myers Squibb, Caribou, Fate Therapeutics, Genentech/Roche, Janssen/Pharmacyclics, Kite, Lily/Loxo, Merck, Morphosys, Sana, and Xencor; and research support paid to their institution has been received from Abbvie, Adaptive, Adicet, AstraZeneca, Bristol Myers Squibb, Caribou, Century, CRISPR, Fate Therapeutics, Genentech/Roche, Janssen/Pharmacyclics, Kite, Lily/Loxo, Merck, Nurix, Sana, and Xencor. Gold has received research support and honoraria from Bayer Schering, Biogen-Idec, Bristol Myers Squibb, Chugai, Eisai, ELAN, Janssen, Kyverna, Merck Serono, Nikkiso Pharma, Novartis, Roche, Sanofi-Genzyme, and TEVA; and consulting honoraria from ZLB Behring, Baxter, Talecris, and Kyverna. Gold has private stock from Kyverna, Merck, Novartis, and Roche.
The video presents a satellite symposium titled ‘CAR T Therapy: The NEX-T Frontier in MS’ was held at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The symposium discussed current unmet needs and future advances in the management of multiple sclerosis (MS). Underlying the symposium was the importance of early intervention with disease-modifying therapy (DMT) in people with MS. Considering the ‘next frontier’ in MS, the critical role of B cells in chronic CNS inflammation was described. While anti-CD20 therapies have proven efficacy for relapsing forms of MS, they have failed to prevent long-term disability in progressive MS and their chronic use is associated with increased infection risk. High doses may have greater penetrance/benefit, but a high cumulative dose of anti-CD20 therapy may be associated with increased safety concerns. CD19 or B cell maturation antigen (BCMA) CAR-T cell therapy can cross the blood–brain barrier and may allow for a deep but non-sustained B cell depletion with immune reset. Efficacy and safety results available thus far support further investigation of CAR-T cell treatments in controlled clinical trials in people with MS.
Moderator
Tyler Campbell1
Speakers
Claire Riley2
Krish Patel3
Ralf Gold4
1. MS Patient Advocate, Austin, Texas, USA
2. Columbia University Irving Medical Center, New York, USA
3. Swedish Cancer Institute, Seattle, Washington, USA
4. St. Josef-Hospital/Ruhr-University Bochum, Germany
HE-GB-2500080
May 2025
